Teva Pharmaceutical Industries Quarterly Income Statement
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Teva Pharmaceutical Industries revenue and earnings
In the quarter ended Jun 30, 2026, Teva Pharmaceutical Industries generated $4.14 billion in revenue, down 0.8% from the same quarter a year earlier. Teva Pharmaceutical Industries reported a net loss of $576.0 million, compared with net income of $282.0 million a year earlier. Gross margin was 52.0% (up from 50.3%) and operating margin -5.6%.
Diluted earnings per share came in at -$0.49, down from $0.24.
Summary generated from market data by MetaCap's automated system. Methodology
Teva Pharmaceutical Industries income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.14B | 3.98B | 1.50B | 4.48B | 4.18B | 3.89B | 4.23B | 4.33B | 4.16B | 3.82B | 4.46B | 3.85B |
| Revenue growth (YoY) | -0.81% | +2.34% | -64.53% | +3.42% | +0.29% | +1.89% | -5.12% | +12.52% | +7.37% | +4.32% | +14.75% | +7.09% |
| Cost of Revenue | 1.99B | 2.01B | 2.06B | 2.18B | 2.07B | 2.01B | 2.11B | 2.18B | 2.14B | 2.05B | 2.04B | 2.00B |
| Gross Profit | 2.15B | 1.97B | 2.66B | 2.30B | 2.10B | 1.88B | 2.12B | 2.15B | 2.02B | 1.77B | 2.42B | 1.85B |
| Operating Expenses | 2.38B | 1.32B | 2.36B | 1.42B | 1.65B | 1.36B | 2.15B | 2.20B | 2.03B | 1.99B | 1.66B | 1.51B |
| Research & Development | 970.00M | 222.00M | 267.00M | 256.00M | 244.00M | 247.00M | 247.00M | 240.00M | 269.00M | 242.00M | 227.00M | 253.00M |
| Selling, General & Admin | 1.03B | 1.00B | 1.12B | 973.00M | 959.00M | 919.00M | 952.00M | 924.00M | 939.00M | 886.00M | 902.00M | 844.00M |
| Operating Income | -231.00M | 652.00M | 300.00M | 882.00M | 455.00M | 519.00M | -29.00M | -51.00M | -5.00M | -218.00M | 756.00M | 344.00M |
| Other Income (Expense) | -224.00M | -216.00M | -220.00M | -237.00M | -252.00M | -225.00M | -218.00M | -272.00M | -241.00M | -250.00M | -249.00M | -280.00M |
| Pretax Income | -455.00M | 437.00M | 80.00M | 646.00M | 203.00M | 294.00M | -247.00M | -324.00M | -246.00M | -467.00M | 507.00M | 64.00M |
| Income Tax | 121.00M | 67.00M | -390.00M | 214.00M | -78.00M | 74.00M | 28.00M | 69.00M | 630.00M | -52.00M | 41.00M | -12.00M |
| Net Income | -576.00M | 369.00M | 480.00M | 433.00M | 282.00M | 214.00M | -217.00M | -437.00M | -846.00M | -139.00M | 463.00M | 69.00M |
| Net Income growth (YoY) | -304.26% | +72.43% | — | — | — | — | -146.87% | -733.33% | — | — | — | +13.11% |
| EPS (Basic) | -0.49 | 0.32 | 0.41 | 0.38 | 0.25 | 0.19 | -0.19 | -0.39 | -0.75 | -0.12 | 0.42 | 0.06 |
| EPS (Diluted) | -0.49 | 0.31 | 0.42 | 0.37 | 0.24 | 0.18 | -0.19 | -0.39 | -0.75 | -0.12 | 0.42 | 0.06 |
| Shares Outstanding (Basic) | 1.17B | 1.16B | — | 1.15B | 1.15B | 1.14B | — | 1.13B | 1.13B | 1.12B | — | 1.12B |
| Shares Outstanding (Diluted) | 1.17B | 1.18B | — | 1.16B | 1.16B | 1.16B | — | 1.13B | 1.13B | 1.12B | — | 1.14B |
| EBITDA | 10.00M | 891.00M | 560.00M | 1.13B | 706.00M | 763.00M | 240.00M | 208.00M | 254.00M | 54.00M | 1.02B | 627.00M |
| Gross Margin | 51.98% | 49.52% | 177.07% | 51.43% | 50.34% | 48.24% | 50.15% | 49.58% | 48.61% | 46.37% | 54.18% | 48.08% |
| Operating Margin | -5.58% | 16.37% | 20.00% | 19.69% | 10.90% | 13.34% | -69.00% | -118.00% | -12.00% | -5.71% | 16.96% | 8.94% |
| Net Margin | -13.91% | 9.27% | 32.00% | 9.67% | 6.75% | 5.50% | -5.13% | -10.09% | -20.32% | -3.64% | 10.39% | 1.79% |
This table shows 12 quarterly periods of Teva Pharmaceutical Industries's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TEVA's reporting calendar. What is a income statement?